CodeMap® Compliance Briefing: 10/07/2011
Editor's Welcome: Palmetto GBA, the Medicare Administrative Contractor (MAC) for California, Hawaii, Nevada, Guam and American Samoa, has published a draft Local Coverage Determination (LCD) that will affect a wide variety of laboratory developed tests (LDTs) and DNA based tests currently reported using nonspecific "stacks" of molecular diagnostic codes. This proposed policy could have far reaching effects if it is adopted by other Medicare contractors and/or commercial payers as a means of limiting coverage and setting payment levels for many proprietary tests, especially DNA based assays. Today, we will summarize Palmetto's proposed policy and how it will apply to various tests and providers. As always, please contact us via email if you have any questions or comments.
Gregory Root, Esq.
Palmetto LCD for Molecular Diagnostic Tests
by: Dr. Charles B. Root
Sorry, access to this content requires a current subscription.
Click here for publications catalog.
CPT copyright 2021 American Medical Association. All rights reserved.
* The responsibility for the content of any "National Correct Coding Policy" included in this product is with the Centers for Medicare and Medicaid
Services and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable to or related
to any use, nonuse, or interpretation of information contained in this product.